Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632702 | 0.85 | CNR2 (0.48) | TAAR1TSHRNR1H2NR1H3CNR2 | |
| SCHEMBL633000 | 0.81 | GRIN2A (0.43) | NR1H2NR1H3MAPTGRIN1GRIN2A | |
| SCHEMBL632294 | 0.81 | TRPM5 (0.50) | TAAR1TSHRNR1H2NR1H3MAPT | |
| SCHEMBL633148 | 0.81 | NOX1 (0.52) | TAAR1TSHRCNR2MAPTNPSR1 | |
| SCHEMBL631574 | 0.80 | TAAR1 (0.46) | TAAR1TSHRMAPTCRHBPCRHR2 | |
| SCHEMBL632206 | 0.79 | ALDH1A1 (0.40) | TAAR1CNR2MAPTDHFR | |
| SCHEMBL631727 | 0.77 | TAAR1 (0.57) | TAAR1MAPT | |
| SCHEMBL631935 | 0.76 | S1PR1 (0.47) | NR1H2NR1H3MAPT | |
| SCHEMBL633125 | 0.76 | CNR2 (0.42) | CNR2 | |
| SCHEMBL631671 | 0.76 | NR1H2 (0.42) | TAAR1TSHRNR1H2NR1H3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | TAAR1 419/4885TSHR 2098/4885NR1H2 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.